生物技术公司Intellia Therapeutics宣布，美国食品药品监督管理局（FDA）已解除对其针对转甲状腺素蛋白淀粉样变性心肌病（ATTR-CM）的Magnitude三期临床试验的临床暂停令。这一决定意味着该重要临床研究项目将得以重新启动并继续推进。
生物技术公司Intellia Therapeutics宣布，美国食品药品监督管理局（FDA）已解除对其针对转甲状腺素蛋白淀粉样变性心肌病（ATTR-CM）的Magnitude三期临床试验的临床暂停令。这一决定意味着该重要临床研究项目将得以重新启动并继续推进。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.